Litigation Details for BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. SANDOZ, INC. (D.N.J. 2017)
✉ Email this page to a colleague
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. SANDOZ, INC. (D.N.J. 2017)
| Docket | ⤷ Start Trial | Date Filed | 2017-10-20 |
| Court | District Court, D. New Jersey | Date Terminated | 2018-05-02 |
| Cause | 15:1126 Patent Infringement | Assigned To | Michael Andre Shipp |
| Jury Demand | None | Referred To | Lois H. Goodman |
| Patents | 8,426,586; 8,545,884; 9,539,258; RE43,431 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. SANDOZ, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. SANDOZ, INC. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-10-20 | External link to document | |||
| 2017-10-20 | 1 | United States Patent Nos. RE 43,431 (“the ’431 patent”); 8,426,586 (“the ’586 patent”); and 9,539,258…United States Patent Nos. RE 43,431; 8,426,586; and 9,539,258 (collectively, the “patents-in-suit”). Plaintiffs…Unenforceability and/or Non-infringement for U.S. Patent Nos. RE 43,431, 8,426,586, 9,539,258, and 8,545,884 Pursuant…matter in controversy involves United States Patent No. 8,426,586 and the same drug product: … US 8,426,586 B2 Page 2 FOREIGN PATENT DOCUMENTS | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
